Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new study is raising concerns about the mental health of type 2 diabetes patients who stop taking GLP-1 receptor agonist drugs. Until now, doctors haven’t had much information about how stopping these medications affects patients psychologically. To find out more, researchers dug through electronic health records, tracking cases of depression and anxiety both while patients were on the medication and after they stopped.
The good news first: while patients were actually taking these drugs, they weren’t more likely to develop psychiatric problems compared to people on other diabetes treatments. In fact, the main drug studied showed fewer psychiatric issues than SGLT2 inhibitors, another common diabetes medication. This lines up with an earlier review of multiple studies, which found the same thing: these drugs appear safe for mental health as long as patients keep taking them.
But things looked very different once patients stopped. People who had been on the medication were more likely to develop depression or anxiety after quitting. Part of this could be explained by rising triglyceride levels (a type of fat in the blood) after stopping the drug, but that wasn’t the whole story. Something else seems to be going on too, and researchers aren’t yet sure what.
This is a surprising contrast to what we know from clinical trials. One trial, for example, found that semaglutide actually helped improve patients’ decision-making. So it seems these drugs may offer real mental health benefits while being used but that protection fades quickly once treatment stops.
Because of this, the researchers say doctors should keep a closer eye on patients after they come off this treatment. Simple check-ins that ask about mood could help catch problems early whether patients stopped the drug because of cost, side effects, or any other reason. Doctors may want to build regular mental health check-ins into their routine care for these patients.
One limitation: the study relied on just one database, so the results might not apply to everyone. Still, the fact that the drug looked protective during treatment and risky after stopping makes the pattern more convincing. More research across different patient groups is needed to fully understand what’s happening. In the meantime, doctors and patients should talk about these mental health risks before deciding to stop treatment.
